Free Trial

Carisma Therapeutics (CARM) Competitors

Carisma Therapeutics logo
$0.18 +0.01 (+4.78%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$0.18 -0.01 (-5.05%)
As of 05/22/2025 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CARM vs. BLUE, KZR, FGEN, MRNS, INKT, ALLK, SCLX, CALC, GRCE, and SRZN

Should you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include bluebird bio (BLUE), Kezar Life Sciences (KZR), FibroGen (FGEN), Marinus Pharmaceuticals (MRNS), MiNK Therapeutics (INKT), Allakos (ALLK), Scilex (SCLX), CalciMedica (CALC), Grace Therapeutics (GRCE), and Surrozen (SRZN). These companies are all part of the "pharmaceutical products" industry.

Carisma Therapeutics vs.

bluebird bio (NASDAQ:BLUE) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

87.4% of bluebird bio shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 1.4% of bluebird bio shares are held by company insiders. Comparatively, 12.6% of Carisma Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Carisma Therapeutics has lower revenue, but higher earnings than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bluebird bio$83.81M0.58-$211.91M-$41.32-0.12
Carisma Therapeutics$19.63M0.39-$86.88M-$1.56-0.12

bluebird bio presently has a consensus target price of $44.60, suggesting a potential upside of 793.79%. Carisma Therapeutics has a consensus target price of $1.93, suggesting a potential upside of 944.49%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than bluebird bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
bluebird bio
0 Sell rating(s)
6 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Carisma Therapeutics
0 Sell rating(s)
5 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.43

bluebird bio has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500.

In the previous week, bluebird bio had 2 more articles in the media than Carisma Therapeutics. MarketBeat recorded 2 mentions for bluebird bio and 0 mentions for Carisma Therapeutics. bluebird bio's average media sentiment score of 0.16 beat Carisma Therapeutics' score of 0.00 indicating that bluebird bio is being referred to more favorably in the media.

Company Overall Sentiment
bluebird bio Neutral
Carisma Therapeutics Neutral

Carisma Therapeutics has a net margin of -314.78% compared to bluebird bio's net margin of -565.74%. bluebird bio's return on equity of -322.46% beat Carisma Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
bluebird bio-565.74% -322.46% -53.17%
Carisma Therapeutics -314.78%-957.20%-96.39%

bluebird bio received 1023 more outperform votes than Carisma Therapeutics when rated by MarketBeat users. However, 78.26% of users gave Carisma Therapeutics an outperform vote while only 70.34% of users gave bluebird bio an outperform vote.

CompanyUnderperformOutperform
bluebird bioOutperform Votes
1041
70.34%
Underperform Votes
439
29.66%
Carisma TherapeuticsOutperform Votes
18
78.26%
Underperform Votes
5
21.74%

Summary

Carisma Therapeutics beats bluebird bio on 10 of the 19 factors compared between the two stocks.

Get Carisma Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CARM vs. The Competition

MetricCarisma TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$7.70M$6.47B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-0.129.0626.7119.71
Price / Sales0.39251.51386.08120.53
Price / CashN/A65.8538.2534.62
Price / Book0.286.456.774.50
Net Income-$86.88M$143.98M$3.23B$248.22M
7 Day Performance10.76%0.38%0.48%-0.78%
1 Month Performance-15.42%2.14%9.10%11.53%
1 Year Performance-85.37%-0.33%18.56%8.99%

Carisma Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CARM
Carisma Therapeutics
2.4575 of 5 stars
$0.18
+4.8%
$1.93
+944.5%
-86.9%$7.70M$19.63M-0.1220Gap Up
BLUE
bluebird bio
2.7122 of 5 stars
$3.29
-6.0%
$44.60
+1,255.6%
-74.6%$32.21M$83.81M-0.09520High Trading Volume
KZR
Kezar Life Sciences
4.1458 of 5 stars
$4.23
+0.2%
$39.50
+833.8%
-48.2%$30.90M$7M-0.3260Gap Up
FGEN
FibroGen
4.3653 of 5 stars
$0.31
-0.8%
$10.00
+3,174.4%
-73.3%$30.86M$29.62M-0.25570
MRNS
Marinus Pharmaceuticals
1.8704 of 5 stars
$0.55
-0.2%
$4.79
+771.6%
-57.4%$30.32M$30.99M-0.22110News Coverage
Analyst Forecast
INKT
MiNK Therapeutics
2.5721 of 5 stars
$7.60
+8.1%
$37.50
+393.4%
-25.9%$30.14MN/A-1.9530Earnings Report
Analyst Revision
ALLK
Allakos
4.2054 of 5 stars
$0.33
+0.3%
$2.00
+506.8%
N/A$29.79MN/A-0.16190
SCLX
Scilex
1.5589 of 5 stars
$4.10
+2.2%
$455.00
+10,997.6%
-88.4%$28.50M$56.59M-4.9480High Trading Volume
CALC
CalciMedica
2.0188 of 5 stars
$2.01
+0.5%
$18.00
+795.5%
-68.8%$28.08MN/A-1.8630
GRCE
Grace Therapeutics
1.8393 of 5 stars
$2.72
flat
$12.00
+341.2%
N/A$27.58MN/A-2.34N/A
SRZN
Surrozen
2.9738 of 5 stars
$8.00
-4.2%
$38.50
+381.3%
-22.8%$26.25M$10.66M-0.3280

Related Companies and Tools


This page (NASDAQ:CARM) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners